Title |
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
|
---|---|
Published in |
Journal of Thoracic Oncology, May 2016
|
DOI | 10.1016/j.jtho.2016.05.008 |
Pubmed ID | |
Authors |
Daniel S.W. Tan, Sue S. Yom, Ming S. Tsao, Harvey I. Pass, Karen Kelly, Nir Peled, Rex C. Yung, Ignacio I. Wistuba, Yasushi Yatabe, Michael Unger, Philip C. Mack, Murry W. Wynes, Tetsuya Mitsudomi, Walter Weder, David Yankelevitz, Roy S. Herbst, David R. Gandara, David P. Carbone, Paul A. Bunn, Tony S.K. Mok, Fred R. Hirsch |
Abstract |
Mutations in the epidermal growth factor receptor (EGFR) represent one of the most common "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKI) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of osimertinib, a 3(rd) generation EGFR TKI, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer (IASLC) commissioned consensus statement, key pathologic, diagnostic and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of re-biopsies and use of circulating free DNA (cfDNA) for molecular studies. With the rapid pace of progress in treating EGFR mutant NSCLC, this statement provides a state-of-the-art review of the contemporary issues in managing this unique subgroup of patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 33% |
Portugal | 1 | 33% |
Ecuador | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 2% |
United Kingdom | 1 | <1% |
Denmark | 1 | <1% |
Unknown | 166 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 30 | 18% |
Other | 21 | 12% |
Student > Postgraduate | 18 | 11% |
Student > Ph. D. Student | 16 | 9% |
Student > Master | 14 | 8% |
Other | 32 | 19% |
Unknown | 40 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 73 | 43% |
Biochemistry, Genetics and Molecular Biology | 24 | 14% |
Agricultural and Biological Sciences | 10 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
Computer Science | 3 | 2% |
Other | 11 | 6% |
Unknown | 46 | 27% |